Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Sei Investments Co.

Sei Investments Co. trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.8% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 212,857 shares of the pharmaceutical company’s stock after selling 1,612 shares during the period. Sei Investments Co. owned 0.08% of Vertex Pharmaceuticals worth $99,772,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VRTX. University of Texas Texas AM Investment Managment Co. acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $25,000. GHP Investment Advisors Inc. bought a new position in Vertex Pharmaceuticals during the second quarter worth $29,000. Annapolis Financial Services LLC acquired a new position in Vertex Pharmaceuticals in the first quarter worth $27,000. Stephens Consulting LLC bought a new stake in Vertex Pharmaceuticals during the second quarter valued at $31,000. Finally, ICA Group Wealth Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $28,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Down 2.7 %

Shares of Vertex Pharmaceuticals stock opened at $464.92 on Friday. The business has a fifty day simple moving average of $482.66 and a 200-day simple moving average of $452.12. The firm has a market cap of $119.97 billion, a price-to-earnings ratio of 30.17 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $341.85 and a fifty-two week high of $510.64. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The business had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter last year, the business posted $3.53 EPS. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the completion of the sale, the chief marketing officer now owns 30,099 shares in the company, valued at approximately $14,198,300.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Bruce I. Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $20,320,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Carmen Bozic sold 2,280 shares of the company’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $471.72, for a total transaction of $1,075,521.60. Following the completion of the sale, the chief marketing officer now owns 30,099 shares of the company’s stock, valued at approximately $14,198,300.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,047 shares of company stock worth $16,843,806. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on VRTX shares. Canaccord Genuity Group lifted their price target on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a report on Wednesday, July 31st. HC Wainwright lifted their target price on Vertex Pharmaceuticals from $500.00 to $600.00 and gave the company a “buy” rating in a research note on Monday, August 5th. TD Cowen increased their price target on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Royal Bank of Canada reissued a “sector perform” rating and issued a $431.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday. Finally, Guggenheim upped their price objective on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $486.36.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.